Blossom Health has raised $20 million in seed and Series A funding to bring an AI “copilot” for psychiatry to patients nationwide, Fortune has exclusively learned. The announcement comes as venture dollars have largely chased more generic AI plays, but as investors have increasingly begun to fund AI enabled health tech. The New York–based startup is positioning itself as an AI‑native psychiatry platform, arguing that the technology finally makes it possible to scale high‑quality mental health care without flooding clinics with more staff.
The round, led by Headline with participation from Village Global, TA Ventures, Operator Partners, and Correlation Ventures, also adds Headline cofounder Mathias Schilling to the board.
“We’ve been very intentional and disciplined around capital raising,” founder and CEO John Zhao told Fortune, noting that all of Blossom’s rounds were oversubscribed but that the company “could raise more, but we choose not to.” Capital, he added, “is both a weapon and a liability.”
Zhao, who previously worked at two hyperscale startups—Athelas, now a multibillion‑dollar company, and online insurance marketplace EverQuote, which he helped scale through an IPO—frames Blossom as a chance to build a “generational company” in mental health. “As long as there are human beings, we’re going to need healthcare, and mental health is only a larger and larger component of each person’s holistic health,” he said.
